Sonoma Pharmaceuticals Expands Product Reach with Multiple Launches
Sonoma Pharmaceuticals, Inc. (SNOA) filed its 10-K report, detailing significant business updates and product launches. The company has focused on increasing revenues and progressing towards profitability, with revenue growth driven by distribution network expansion, new product introductions, and organic growth. Key developments include the U.S. retail launch of a burn relief hydrogel in CVS and Walmart, the introduction of a new dermatology product line for sensitive skin, and the registration of a facial spray under the FDA's MoCRA. The company also announced new wound cleanser launches, received prestigious seals for its Reliefacyn product, and expanded its product availability in major U.S. retailers and internationally, including the UK and Ukraine.
Key Highlights
- Sonoma Pharmaceuticals launched advanced HOCl-based burn relief hydrogel in CVS and Walmart stores in March 2026.
- Launched Aquanil® AD, a hypochlorous acid based dermatology product line for sensitive skin, in March 2026.
- Registered manufacturing facility and listed Microcyn-based facial spray under FDA's MoCRA in October 2025.
- Launched new HOCl wound cleanser for Medline Industries in October 2025 for distribution in U.S. healthcare channels.
- Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel earned National Psoriasis Foundation Seal of Recognition in August 2025.
- Reliefacyn earned National Rosacea Society Seal of Acceptance in November 2025.
- Launched HOCl-based diaper rash products for infants and children into Walmart and other large retailers in August 2025.
- Expanded partnership with a U.S. distributor for Microcyn technology-based products to large retailers in July 2025.
- Launched hypochlorous acid-based acne products in over 1,200 stores in the UK in April 2025.
- Received regulatory approval for wound care products in Ukraine as a Class IIb medical device in April 2025.
Price Impact
More from SNOA
Sonoma Pharmaceuticals Proposes Reincorporation to Nevada
SNOA Prices $4.0M Public Offering; Expects $3.5M Net Proceeds
Sonoma Pharmaceuticals Enters Manufacturing and Supply Agreement with Kenvue Brands for Microcyn® Products in US